Ames Seed Capital

VetMeasure, Inc. is a company based in Ames, Iowa, founded in 2015 that specializes in animal health monitoring technology. The company has developed MeasureOn, a wearable harness that enables veterinarians and pet owners to remotely monitor vital health statistics of dogs and other pets. This device tracks parameters such as heart and pulse rates, respiration, body temperature, and ambient conditions, providing real-time data to assess an animal's health status, particularly following surgical procedures or during illness. Utilizing Bluetooth technology and a web application, MeasureOn facilitates accurate health monitoring, enhancing the ability to respond to changes in an animal's condition promptly.

Pitchly, Inc. is a technology company that offers a cloud-based content services platform tailored for merger and acquisition professionals. Founded in 2014 and based in Des Moines, Iowa, Pitchly's platform allows users to create and manage custom databases that catalog proprietary experience and intellectual property. The service is designed for investment banks, accounting firms, and law firms, enabling non-technical users to easily generate data-driven documents in PowerPoint and Word, linking to various internal data sources such as Excel, SQL, and Salesforce. By aggregating disparate information, Pitchly significantly reduces the time needed to create complex documents and eliminates errors, thus enhancing efficiency in data management and presentation. Users can also create custom forms to ensure they are accessing the most current data, further streamlining their workflows.

Automed Inc. specializes in designing and manufacturing automatic livestock medication systems aimed at enhancing operational efficiency for livestock producers. Founded in 2012 and based in Belconnen, Australia, the company offers an innovative system that automatically calculates, delivers, and records livestock treatments. This system is compatible with various livestock tools and farm management platforms, allowing seamless integration into existing operations. The automed device can administer medication through methods such as injection, drench, pour-on, and intra-nasal applications, ensuring accuracy and efficiency. By utilizing the automed app, users can manage both fixed and weight-based treatments in real-time, thereby improving compliance, disease prevention, and overall traceability in livestock management.

FindBob is a transition management platform designed for financial advisors and insurance agents, focusing on growth, transition, and succession planning. By leveraging machine learning and gamification, the platform simplifies the transition process for advisors and firms. It aims to cultivate a growth-oriented culture within the financial advisory industry by facilitating safe opportunity discovery and internal adjustments. FindBob's tools enable clients to protect their assets, attract and retain talent, generate new revenue, and ensure that advisory practices adhere to fiduciary obligations.

NewLink Genetics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immuno-oncology products aimed at enhancing the quality of life for cancer patients. Established over 15 years ago, the company is driven by a team of industry professionals and physician-scientists committed to advancing cancer treatments. Inspired by personal experiences with cancer, NewLink Genetics focuses on transformative research and development efforts to shift the paradigm of cancer care and improve patient outcomes.

NewLink Genetics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immuno-oncology products aimed at enhancing the quality of life for cancer patients. Established over 15 years ago, the company is driven by a team of industry professionals and physician-scientists committed to advancing cancer treatments. Inspired by personal experiences with cancer, NewLink Genetics focuses on transformative research and development efforts to shift the paradigm of cancer care and improve patient outcomes.